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Guanine monophosphate (GMP) synthetase is a bifunctional two-domain enzyme. The N-terminal
glutaminase domain generates ammonia from glutamine and the C-terminal synthetase domain aminates
xanthine monophosphate (XMP) to form GMP. Mammalian GMP synthetases (GMPSs) contain a
130-residue-long insert in the synthetase domain in comparison to bacterial proteins. We report here the
structure of a eukaryotic GMPS. Substrate XMP was bound in the crystal structure of the human GMPS
enzyme. XMP is bound to the synthetase domain and covered by a LIDmotif. The enzyme forms a dimer in the
crystal structure with subunit orientations entirely different from the bacterial counterparts. The inserted
sub-domain is shown to be involved in substrate binding and dimerization. Furthermore, the structural basis
for XMP recognition is revealed as well as a potential allosteric site. Enzymes in the nucleotide metabolism
typically display an increased activity in proliferating cells due to the increased need for nucleotides. Many
drugs used as immunosuppressants and for treatment of cancer and viral diseases are indeed nucleobase-
and nucleoside-based compounds, which are acting on or are activated by enzymes in this pathway. The
information obtained from the crystal structure of human GMPS might therefore aid in understanding
interactions of nucleoside-based drugs with GMPS and in structure-based design of GMPS-specific inhibitors.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
De novo synthesis of guanine nucleotides is
essential for DNA and RNA synthesis. It also provides
GTP, which is a key regulator and energy source in
many cellular processes. Furthermore, it is involved in
a number of cellular processes required for cell
division. The final step in the de novo synthesis of
guaninemonophosphate (GMP) is catalyzed by GMP
synthetase (GMPS; E.C. 6.3.5.2). GMPS belongs to
the class 1 glutamine-dependent amidotranferases
possessing a conserved catalytic triad consisting of a
Cys, His, and Glu residue [1]. It catalyzes the
conversion of xanthine monophosphate (XMP) to
GMP in the presence of glutamine and ATP through
an adenyl-XMP intermediate [2,3]. It is a bifunctionalthors. Published by Elsevier Ltd. Open access uenzymewith two domains; theN-terminal glutaminase
(GATase) domain generates ammonia from gluta-
mine further used by the C-terminal synthetase
domain to aminate XMP to yield GMP [4].
Several enzymes in the mammalian nucleotide
metabolism display an increased activity in rapidly
dividing cells due to an increased demand for
nucleotides, thus making these enzymes targets
for anti-cancer therapy [5]. Human GMPS (hGMPS)
is also identified as a potential target for anti-cancer
therapy [6–8]. Several glutamine analogs, like
acivicin and 6-diazo-5-oxo-L-norleucine (DON) that
bind covalently to the GATase site, have been
observed to inhibit GMPS [9,10]. The preceding step
in the de novo pathway making XMP from IMP is
performed by IMP dehydrogenase and inhibitors ofJ. Mol. Biol. (2013) 425, 4323–4333nder CC BY-NC-ND license. 
4324 Crystal Structure of Human GMP Synthetasethis enzyme are now used for immunosuppressive
and anti-viral chemotherapy [11]. There appears to
be also additional roles for hGMPS in the cell.
Drosophila GMPS is apparently involved in chroma-
tin regulation [12] and axon guidance [13] and
recently it was shown that hGMPS can allosterically
enhance the activation of the ubiquitin-specific
protease USP7/HAUSP [14].
Several GMPSs have been biochemically charac-
terized, among these are hGMPS, as well as GMPS
from Escherichia coli (EcGMPS), Pyrococcus hori-
koshii OT3 GMPS (PhGMPS), and Plasmodium
falciparum GMPS [15–21]. Previously, a monomeric
enzyme of hGMPS has been observed in solution
[18,21]. The activity of hGMPS displays positive
cooperativity for the substrate XMP, indicating alloste-
ric regulation [18,21]. Structural information of
GMPSs is available for several bacterial and
archaeal enzymes. Structures of EcGMPS in com-
plex with AMP and pyrophosphate, Thermus thermo-
philus GMPS in complex with XMP [TtGMPS;
Protein Data Bank (PDB) ID: 2YWC], and the apo
form of PhGMPS have been determined and show
similar overall folds and dimeric structures [1,20].
EcGMPS was the first GMPS structure to be
determined and revealed a distance between the
two active sites of ca 30 Å [1]. During the reaction,
the ammonia needs to be relocated from the
GATase domain to the synthetase domain either
by channeling or by domain rearrangement [1,4,22].
Here, we present the first structure of a eukaryotic
GMPS, hGMPS, in complex with XMP. Interestingly,
the structure reveals an additional sub-domain in-
volved in substrate binding and dimerization. Further-
more, the structure defines the substrate specificity
determinants for XMP. The fact that the hGMPSdiffers
from its bacterial and archaeal counterpart by having
an additional dimerization sub-domain interacting with
the active site could be exploited in the development of
potential anti-bacterial or anti-parasitic drugs.Results
Overall structure of hGMPS
The structure of the hGMPS in complex with its
substrate XMPwas determined at 2.5 Å resolution. A
monomer encompassing residues 20–693 of GMPS
is composed of two catalytic domains, an N-terminal
GATase domain (20–210) and a C-terminal synthe-
tase domain (residues 220–693). The asymmetric
unit contains a dimer. Residues 25–693 and 23–693
have been modeled for subunits A and B, respec-
tively (Fig. 1a), with the exception of some flexible
regions with no electron density in chain A (35–36,
79–85, 121–127, 312–321) and in chain B (123–125,
312–321). Although GMPS was co-crystallized withXMP, AMPPNP, andmagnesium, only XMP is visible
in the electron density map (Fig. 1b). Three sulfate
ions are bound to each subunit (S1, S2, and S3). The
synthetase domain can be divided into three sepa-
rate sub-domains, an ATP pyrophosphatase (ATP-
Pase) domain, and two dimerization domains
(Fig. 1a), while the GATase domain is composed of
a single structural domain.
GATase domain
The GATase domain is composed of a central
β-sheet surrounded by mainly α-helices, comprising
the catalytic triad Cys104, His190, and Glu192
(Fig. 1c). A DALI search [23] of this domain reveals
similarity to other GATase domains of amidotran-
serases with the GATase domain of EcGMPS as the
closest structural homolog with a root-mean-square
deviation (r.m.s.d.) of 1.5 Å for 175 amino acids.
Currently, there is no experimental structural infor-
mation of glutamine binding to the GATase domain
of a GMPS, but based on homology, it is expected to
bind glutamine similarly as anthranilate synthase
[24]. The ammonium generated by the GATase
domain is utilized by the ATPPase domain located
near the GATase domain in the structure (Fig. 1a).
The active site of the GATase domain where the
ammonia is generated is situated ca 40 Å away from
the bound XMP to the synthetase domain, making it
necessary for ammonia to be transferred by an
unknown mechanism to the second active site.
ATPPase domain
The ATPPase sub-domain of hGMPS is composed
of a five-stranded parallel β-sheet sandwiched
between nine α-helices (Fig. 1b). The substrate
XMP is bound to this sub-domain. Residues 368–
408 form a lid-like region (in the following referred to
as the lid) closing in over the active site (Fig. 1b and
d). One of the sulfate ions (S1) found in the structure
is bound to a conserved phosphate binding loop
composed of residues 244–250 and occupying the
binding site for the phosphate moiety of ATP in the
structure of EcGMPS (PDB ID: 1GPM) [25].
Oligomerization
Since hGMPS possesses two dimerization sub-
domains, the dimer organization is completely
different from its bacterial counterparts. Of the total
surface area, ~20% (~10,000 Å [2]) is buried upon
formation of the dimer. Also, for eukaryotic se-
quences, the dimer displays a higher level of
conservation around the dimer interface (Fig. 2a).
There are fewer conserved residues in the D1 sub-
domain except around the β-hairpin, which is highly
conserved (Fig. 2b). Since the crystal structure
supports the notion that hGMPS is a dimeric enzyme,
Fig. 1. Structure of hGMPS. (a) The subunit structure of GMPS containing the GATase domain (blue), ATPPase
sub-domain (gray), and dimerization sub-domain 1 (D1) (yellow) and 2 (D2) (red). The catalytic triad of the GATase (residues:
Cys104, His190, andGlu192) are shown as yellow sticks. XMPand sulfate ions bound are also shown as sticks. (b) ATPPase
sub-domain of hGMPS. The LID region consisting of residues 368–408 is colored red. The ATPPase domain is colored gray.
(c) Close-up view of the catalytic triad of the GATase domain; residues are shown in sticks in orange. (d) LID region. The LID
region is displayed in cartoon and the other domains of hGMPS are shown with surface, colored red and white, respectively.
4325Crystal Structure of Human GMP Synthetasein contrast with earlier data [18,21], analytical gel
filtration was performed to elucidate the oligomeric
state of hGMPS in solution. A large peak correspond-
ing to a monomer was observed when size-exclusion
chromatography was run in the presence of
XMP + Mg, ATP + Mg, XMP + ATP + Mg, and with-
out substrates. However, a small additional peak was
observed prior to monomer peak with a size corre-
sponding to approximately a dimer (Fig. 2c), indicating
a small dimer population in solution. To further
investigate the oligomeric state, we performed cross-
linking experiments in the presence of glutamine
analogs DON and azaserine, known to bind to the
glutamine binding site of the GATase domain [26].
These experiments were performed together withXMP, ATP, and Mg2+ to trap an active state of the
protein. Dimerization was induced in the presence of
DON, while azaserine or the apo form of GMPS did not
form dimers (Fig. 2d). This suggests that the active
form of hGMPS, containing all co-substrates, could be
a dimer.
Dimerization sub-domains
Mammalian GMPSs contain a long insert that
stretches from residue 450 to residue 578 constitut-
ing the D1 sub-domain, which is absent in bacterial
and archaeal counterparts (Fig. 3). This sub-domain
is built up by an anti-parallel three-stranded β-sheet,
where the middle β-strand stretches out to form a β-
4326 Crystal Structure of Human GMP Synthetasehairpin. The β-sheet is flanked by five α-helices. In
the structure, this sub-domain is involved in dimer-
ization and substrate binding (Fig. 1a). Interestingly,
the β-hairpin (Ile514–Tyr528) stretches into the XMP
binding site of the other subunit in the dimer, where
Arg524 from the β-hairpin in subunit A and Asp522
from the β-hairpin in subunit B interact with each
other and with the phosphate moiety of XMP bound
to subunit A (Fig. 4a). The last 115 residues of
hGMPS (579–693) form a second dimerization
sub-domain, the D2 sub-domain. The fold of the
two dimerization sub-domains D1 and D2 is similarFig. 2. Sequence conservation for hGMPS. (a) hGMPS dim
representation for subunit B colored white, yellow (D1), and red
remaining residues are in dark gray. (b) Cartoon representatio
Arg524 in sticks; same coloring scheme as in (a). (c) Analytic
(d) SDS-PAGE showing the dimer formation in the cross-linkinand superposition of the two sub-domains gives an
r.m.s.d. of 2.2 Å for 73 Cα.
Substrate binding
TheXMPmolecule is bound in the active site located
in between the ATPPase sub-domain and the D2 sub-
domain of the same subunit (Fig. 1a). The lid is closing
in over the active site and the xanthine base is wedged
between a conserved Pro-rich region (residues 438–
441) and a loop containing residues 383–385 of the lid.
Arg337 is the key residue in discriminating XMP fromer using surface representation for subunit A and cartoon
(D2). Highly conserved residues are colored purple and the
n of the D1 sub-domain showing side chains Asp522 and
al size-exclusion chromatography for full-length hGMPS.
g experiment.
4327Crystal Structure of Human GMP Synthetaseother purine monophosphates, making specific in-
teractions to O6 and N7 of the xanthine base (Fig. 4a).
The conformation of this arginine is stabilized by
interactions from the carboxylate group of the C-
terminus of the protein (Fig. 4a). The ribose moiety
makes well-defined interactions with Gln610 and
Glu691 (Fig. 4a). The phosphate moiety of XMP
interacts with residues Arg524, Lys685, Thr690,
Glu691, and Asp522 from the B subunit (Fig. 4b).Fig. 3. Structure-based sequence alignment of the GMPS s
EcGMPS. Sub-domains are color coded as in Fig. 1a. The LID
are shown for hGMPS and EcGMPS above and below the aliThe hydrogen bonding of a carboxylate residue
(Glu691) with the ribose hydroxyl is a common motif
for specific recognition of ribonucleotides [27].
The high concentration of ammonium sulfate in the
crystallization condition likely explains why the
AMPPNP does not bind to the ATP binding site in
the crystal. The sulfate S1 bound in the phosphate
binding loop (Fig. 1b) makes hydrogen bonds to the
side chain of Ser244 and main chain of Ser249.ynthetase domains from human, TtGMPS, PhGMPS, and
is marked in the alignment. Secondary-structure elements
gnment.
Fig. 4. Binding of XMP to hGMPS. (a) Interactions with the xanthine base and ribose moiety of XMP. Residues involved
in binding and XMP are shown in sticks colored slate blue and gray. (b) Interactions with the phosphate moiety of XMP.
Residues involved in binding and XMP are shown with sticks using the same coloring. Asp522 from the other subunit is
colored yellow.
4328 Crystal Structure of Human GMP SynthetaseA second sulfate ion (S2) is bound ~12 Å from the
ribose moiety of XMP. S2 is located in a pocket
between the D1 sub-domain and the ATPPase sub-
domain, close to the Pro-rich region lining the
xanthine base (Fig. 1a). Several positively charged
residues are lining the pocket where the sulfate ion is
bound. It is possible that this is a binding site for a
regulatory phosphate-containing molecule although
evidence for this remains to be provided.
Comparison with prokaryotic GMPSs
Comparison of the structures of the bacterial and
archaeal GMPSs with the hGMPS reveals that the
eukaryotic enzyme has several unique attributes. D1
sub-domain in hGMPS is absent in bacterial pro-
teins, but the other domains have a very similarFig. 5. Subunit compositions of different GMPSs. (a) Supe
The domains of GMPS are colored as in Fig. 1: GATase dom
sub-domains 1 and 2 (D1 and D2), yellow and red, respectively
light gray. (c) EcGMPS with the second monomer shown in ligorientation (Fig. 5a). The hGMPS dimer is more
tightly packed (Fig. 5b), whereas the overall shape of
the bacterial and archaeal GMPS dimer is more
open (Fig. 5c). EcGMPS forms a dimer using its
dimerization sub-domain that is built up by a mixed
β-sheet (Fig. 5c) [1]. Comparing the dimerization
sub-domain from prokaryotic GMPSs with the D1
and D2 sub-domains of hGMPS reveals strikingly
similar polypeptide folds of these domains (Fig. 6a)
with an r.m.s.d. of 1.9–2.4 Å according to the DALI
server [23]. The orientation of D1 and D2 sub-
domains in the hGMPS is very similar to the dimer
formed by the sub-domain in the EcGMPS with an
r.m.s.d. of 1.2 Å over 101 residues (Fig. 6b).
Multiple sequence alignment comparing mamma-
lian, bacterial, and archaeal sequences reveals a
region in the unique human D1 sub-domain that isrposition of hGMPS and EcGMPS (magenta) monomers.
ain, blue; ATPPase sub-domain, gray; and dimerization
. (b) Dimer of hGMPS with the second monomer shown in
ht gray.
Fig. 6. Comparison of dimerization domains. (a) Superposition of the dimerization sub-domains D1 (yellow) and D2
(red) of hGMPS, EcGMPS (blue), TtGMPS (green), and PhGMPS (orange). (b) Superposition of hGMPS D1 (yellow) and
D2 (red) sub-domains and the two dimerization sub-domains of EcGMPS dimer (blue). (c) Structure-based sequence
alignment of human D1 with dimerization sub-domains of EcGMPS and PhGMPS. Secondary-structure elements are
shown for hGMPS and PhGMPS above and below the alignment.
4329Crystal Structure of Human GMP Synthetasehighly conserved to a part of the dimerization
sub-domain of bacterial proteins. This region has the
consensus sequence Val-Gly-Val-x-Gly-Asp-x-Arg-x-
Tyr (Fig. 6c) and interestingly it is not present in the D2
domain of hGMPS, which in the monomer structure
superposes with the dimerization domain of EcGMPS
(Fig. 5a). This conserved region of the dimerization
domain is also involved in binding of XMP. In hGMPS,
residues Asp522 and Arg524 are interacting not only
with each other from the opposite subunit but alsowith
the phosphate moiety of XMP (Fig. 4b). In prokaryotic
GMPSs, this β-hairpin is either unstructured or taking
slightly different conformations, indicating flexibility
(Figs. 6a and 5c). In the EcGMPS, the main chain of
the Asp462 corresponding to Asp522 in hGMPS is
situated 34 Å away from the phosphate bound to the
XMP binding site in the same subunit. However, the
distance to the phosphate in the other subunit in the
dimer is 18 Å (Fig. 5c).When the humanD1 domain is
superimposed on the dimerization domain of prokary-
otic GMPSs, it becomes clear that the β-hairpin endsup close to the phosphate moiety of XMP from the
other subunit of the dimer. This indicates that the
conserved aspartic acidmay have an important role in
prokaryotes as well.Discussion
hGMPS possesses a second dimerization sub-
domain not present in bacterial and archaeal
GMPSs.Duplication of thedimerization domainmimics
the dimer seen in bacterial enzymes, but the distance
and orientation between the two active sites in hGMPS
and EcGMPS are similar (Fig. 5) [1]. There appears to
be an equilibriumwith themonomeric and dimeric form
of the enzyme, and under the tested conditions, the
enzyme is mostly a monomer in solution. It is not clear
when and how the dimerization occurs, but it is
enhanced by substrate binding. In the crystal, the
dimeric form could be stabilized by high concentration
and by the nonphysiological precipitant condition.
4330 Crystal Structure of Human GMP SynthetaseBinding of the substrate induces dimer formation
leading to an ordered lid domain, which could play a
role in cooperation of the enzymatic activities and
perhaps in transfer of the ammonia.
The long distance between the active sites and the
lack of a clear route for ammonia transfer indicate
domain rearrangements during reaction as for the
EcGMPS [1]. In contrast to the EcGMPS, there is
also a possibility of an intermonomer transfer of
ammonia through the center of the globular oligomer
due to unique oligomeric packing observed in the
crystal structure. However, as the orientation of the
GATase and ATPPase domains is similar in both
enzymes (Fig. 5), it seems likely that the mechanism
of the ammonia transfer would be also similar. An
intriguing possibility is that the LID domain that has
been disordered in previous crystal structures could
contribute to the cooperation of the active site and
perhaps to the transfer of ammonia.
In EcGMPS, 22 residues of the lid are flexible and
believed to be stabilized upon XMP binding [1]. In the
case of TtGMPS (PDB ID: 2YWC), part of the lid is
flexible albeit XMP binding, indicating that bacterial
GMPSs may require both XMP and ATP for lid
closure. In hGMPS, the D1 sub-domain from the
other subunit in the dimer is partly stabilizing the lid.
The lid in hGMPS is ordered and closes in over both
the ATP and XMP binding sites. The observed
conformation might be the conformation present
during catalysis. Earlier studies of hGMPS have
revealed a monomeric enzyme using density gradient
centrifugation [18,21]. Positive cooperativity was
observed for the substrate XMP and it was speculat-
ed that there would be a second XMP binding site in
hGMPS [18,21]. We observed a potential ligand
binding site marked by S2 located ~12 Å from the
ribose moiety of XMP. S2 is located in a pocket
between the D2 sub-domain and the ATPPase sub-
domain, close to the Pro-rich region lining the
xanthine base (Fig. 1a). This cavity is lined by several
residues appropriate for binding both a phosphate
and a ribosemoiety. However, we have not been able
to obtain evidence that this is indeed an allosteric site
where, for example, XMP could bind. Another, more
likely explanation for the observed positive coopera-
tivity would be that a dimeric protein is induced by
substrate binding. This is supported by the interac-
tions of XMP and residues from the other subunit in
the dimer, indicating cross-talk between the subunits.
In addition, interactions between the lid and the D1
sub-domain of the second subunit could contribute to
cross-talk within the dimer. In solution, we observed
that hGMPS was predominantly a monomer with only
a small population of dimers. The cross-linking
experiments suggest that XMP, ATP, and glutamine
are needed to induce dimer formation in solution.
Asp522 and Arg524 are part of the conservedmotif
in the D1 sub-domain. The fact that Asp522 stretches
in from the other subunit towards the phosphatemoiety is surprising, and the carboxylate phosphate
interaction appears unfavorable. The temperature
factors in the tip of the β-hairpin are higher than those
of the surrounding residues. In the bacterial counter-
part, the conserved aspartic acid is located ~18 Å
from the XMP binding site in the other subunit and
~34 Å away in the same subunit. In TtGMPS, the tip
of the β-hairpin is flexible despite XMP binding. The
superposition of the human D1 sub-domain on
prokaryotic GMPSs indicates that the β-hairpin may
become ordered and swings in towards the XMP
molecule upon substrate binding. One aspect of this
conserved aspartic acid could be to facilitate product
release. In the case of hGMPS, it might play a part in
dimer formation, bringing the two subunits together
with interactions between Asp522 and Arg524.
Since numerous enzymes in the nucleotide
metabolism display an increased activity in prolifer-
ating cells, they might be attractive cancer targets
[5]. Many of the drugs targeting enzymes in the
nucleotide metabolism act on a broader range of
enzymes, which might add potency and might also
be the cause of excessive toxicity [28]. Structural
information on these enzymes is therefore valuable
in efforts directed at developing new, more selective
drugs. Information on structural differences between
human and pathogen enzymes might also assist in
the development of novel antibiotics targeting the
nucleotide metabolism. In times of increasing bac-
terial resistance, there is as well a growing need for
new anti-bacterial agents [29]. Therefore, the struc-
tural information provided in the present work might
be directly useful in therapeutic development.Materials and Methods
Cloning
The GMPS gene clone was obtained from the National
Institutes of Health's Mammalian Gene Collection (acces-
sion no. BC012178). The sequence encoding residues
20–693 and 1–693 were amplified by PCR and inserted
into pNIC28-Bsa4 vector by ligation-independent cloning.
Constructs included an N-terminal tag containing a 6-His
sequence (MHHHHHHSSGVDLGTENLYFQSM). For ex-
pression, the pNIC-Bsa4 containing the insert was
transformed into E. coli BL21(DE3) gold pRARE strain
and stored at −80 °C for further use.
Protein expression
Cells from a glycerol stock were grown in 60 mL of TB
supplemented with 8 g/L glycerol, 100 μg/mL kanamycin,
and 34 μg/mL chloramphenicol at 37 °C overnight. The
overnight culture (60 mL) was used to inoculate three flasks
with 1.5 L of TB each, supplemented with 50 μg/mL
kanamycin and approximately 0.5 mL of Dow Corning
anti-foam RD emulsion 63213 4D (BDH Silicone Products).
4331Crystal Structure of Human GMP SynthetaseThe cultures were grown at 37 °C until OD600 reached ~2.
The flasks were down-tempered to 18 °C over a period of
30 min before target expression was induced by addition of
0.5 mM IPTG. Expression was allowed to continue over-
night and cells were harvested the following morning by
centrifugation (4400g, 20 min, 4 °C) and stored at −80 °C.Table 1. Data and refinement statistics
GMPS
Beam line BL14-2 (BESSY)
Wavelength (Å) 0.97968
Space group P212121
Resolution (Å) 20–2.5 (2.56–2.50)
Cell dimensions
a, b, c (Å) 98.52, 123.42, 127.96
Rmerge 0.094 (0.587)
I/σ(I) 18.9 (4.12)
Completeness (%) 99.7 (100)
Redundancy 7.7 (7.8)
Refinement
No. of reflections 51,746
Rwork
a/Rfree
b 0.203/0.256
No. of atoms
Protein 10,043Protein purification
The frozen cell pellet was re-suspended in lysis buffer
(100 mM Hepes, 500 mM NaCl, 10% glycerol, 10 mM
imidazole, and 0.5 mM TCEP, pH 8.0), supplemented with
0.25 mg of lysozyme, 1000 U Benzonase (Merck), and one
tablet of Complete EDTA-free protease inhibitor (Roche
Applied Science). Cells were disrupted by sonication (Vibra-
Cell, Sonics) at 80% amplitude for 3 min effective time
(pulsed 4 s on, 4 s off), and cell debris was removed by
centrifugation (49,100g, 20 min, 4 °C). The supernatant
was decanted and filtered through a 0.45-μm flask filter.
Purification of the protein was performed as a two-step
process on an ÄKTAxpress system (GE Healthcare). Prior
to purification, columns were equilibrated using lysis buffer
and gel-filtration buffer (20 mM Hepes, 300 mM NaCl, 10%
glycerol, and 2 mMTCEP, pH 7.5). The protein sample was
divided into three equal parts and each was loaded onto a
Ni-charged 1-mLHiTrapChelatingHP (GEHealthcare). The
IMAC columns were washed with wash buffer 1 containing
(20 mM Hepes, 500 mM NaCl, 10% glycerol, 10 mM
imidazole, and 0.5 mM TCEP, pH 7.5) followed by wash
buffer 2 containing (20 mM Hepes, 500 mM NaCl, 10%
glycerol, 25 mM imidazole, and 0.5 mM TCEP, pH 7.5).
Boundproteinwas eluted from the IMACcolumnswith IMAC
elution buffer (20 mM Hepes, 500 mM NaCl, 10% glycerol,
500 mM imidazole, and 0.5 mM TCEP, pH 7.5) and
automatically loaded onto a HiLoad 16/60 Superdex 200
Prep Grade (GE Healthcare) gel-filtration column. Fractions
containing the target protein were pooled. A similar protocol
was used for the expression and purification of the full-length
GMPS. The protein was subsequently concentrated using a
Centricon centrifugal filter device with 30,000 NMWL
(Millipore) to 13.0 mg/mL (truncated enzyme) and 26 mg/
mL (full-length enzyme) and stored at−80 °C. The identity of
the protein was confirmed by mass spectrometry [30].XMP 48
Water 125
Other 30
B-factors (Å2)
Protein 36.8
XMP 23.6
Water 31.3
Other 69.9
r.m.s.d.
Bond lengths (Å) 0.009
Bond angles (°) 1.2
Ramachandran plot (%)c
Favored regions 98
Additionally allowed regions 2Analytical gel filtration
Analytical gel filtration was performed on an Äkta Purifier
using a Superdex 200 10/300 column equilibrated with
20 mM Hepes, 300 mM NaCl, 10% glycerol, and 2.0 mM
TCEP, pH 7.5. GMPS were run in its apo form, with 1 mM
XMP and 10 mMMgCl2, with 1 mMATP and 10 mMMgCl2
and 1 mM XMP, or with 1 mM ATP and 10 mM MgCl2. For
each run, 300 μg of the full-length GMPS was used. The
samples were incubated for 30 min to 1 h before each
gel-filtration run.Rmerge = ∑i|Ii − 〈I〉|/∑〈I〉, where I is an individual intensity mea
surement and 〈I〉 is the average intensity for this reflection with
summation over all data.
Values for the highest-resolution shell are shown in parentheses
a Rwork is defined as∑||Fobs| − |Fcalc||/∑|Fobs|, where Fobs and Fcal
are observed and calculated structure-factor amplitudes, respectively
b Rfree is the R-factor for the test set (5% of the data).
c According to MolProbity [31].Cross-linking assay
Cross-linking experiment with full-length hGMPS was
performed using dimethyl suberimidate. The reaction mixture
contained GMPS at a concentration of 1 mg/mL with 5 mM
MgCl2 in gel-filtration buffer. This mixture was used eitheralone or with the combinations of 1 mM XMP, 1 mM ATP,
5 mM MgCl2, and 1 mM of glutamine analogs DON or
azaserine. After 3 h in room temperature, the reaction was
quenched by addition of 1 M Tris, pH 8. Cross-linking was
then analyzed on SDS-PAGE to visualize dimer formation.
Crystallization, data collection, and structure
determination
Crystals of hGMPS (residues 20–693) were obtained by
the sitting drop vapor diffusion method using 96-well plates
by mixing 0.2 μL of the protein solution (12 mg/mL + 5 mM
XMP + 5 mM AMPPNP + 10 mMMgCl2) with 0.1 μL of the
well solution consisting of 0.1 M sodium acetate trihydrate,
pH 5.2, 1.6 M ammonium sulfate, and 0.2 M sodium
chloride at room temperature. Crystals typically appeared
after 2–5 days and were mounted in a rayon loop and
transferred to a cryo-protectant solution containing 0.1 M
sodiumacetate trihydrate, pH 5.2, 1.6 Mammoniumsulfate,
0.3 M sodium chloride, and 25% glycerol. The crystal was
briefly soaked in the cryo-protectant solution before being
flash frozen in liquid nitrogen. Diffraction data were collected
at BESSY beam line BL14-2 and processed with XDS-
.
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4332 Crystal Structure of Human GMP Synthetase(Table 1) [32]. For molecular replacement, separate
searches were done for each domain using PHASER [33].
As search models, the GATase domain of hGMPS (PDB ID:
2VPI) and the synthetase domain (195–503) of GMPS from
T. thermophilus (PDB ID: 2YWC) were used. The initial
model was then automatically built using PHENIX autobuild
[34]. Final cycles of model building and refinement were
performed in Coot [35] and REFMAC5 [36]. All data
collection and refinement statistics are shown in Table 1.
Structure alignments and analysis
Superposition of the structures were done with Coot [35]
using thesecondary-structurematching-basedalgorithm [37].
All the figures were generated with PyMOL [38]. Structural
sequence alignment was made using STRAP (PDB IDs:
2VXO, 1GPM, 2YWC, and 3A4I) [39]. The multiple align-
ments were carried out using ClustalW2 [40] and visualized
using ESPript [41]. Surface areas were calculated using the
PISA server [42]. To visualize the level of conservation, we
used a multiple alignment with 41 eukaryotic sequences
selected by the ConSurf server [43,44].
Accession number
The coordinates and structure factors have been
deposited to the PDB with the accession code 2VXO.Acknowledgements
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